ERBB2 and breast carcinoma: Cyclin-dependent kinase 4 and 6 inhibitor Ribociclibin hormone receptor-positive, HER2-negative advanced breast cancer with disease progression after endocrine therapy was investigated in double-blind, randomized, phase 3 trials.